NATCO Pharma Limited (NSE:NATCOPHARM)
India flag India · Delayed Price · Currency is INR
919.50
-10.35 (-1.11%)
Jul 31, 2026, 3:30 PM IST

NATCO Pharma Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
14,18518,85413,8837,1531,700
Depreciation & Amortization
2,0661,8121,8221,5921,394
Other Amortization
-40464632
Loss (Gain) From Sale of Assets
251-90117-178-427
Asset Writedown & Restructuring Costs
-530-23-
Loss (Gain) From Sale of Investments
-24-14752-12
Stock-Based Compensation
----22
Provision & Write-off of Bad Debts
89-11278-131470
Other Operating Activities
-5,339-1,345-843-693-400
Change in Accounts Receivable
3,860-593-3,413-2,223-2,389
Change in Inventory
-1,427-653424191564
Change in Accounts Payable
1,333403-2811,02074
Change in Other Net Operating Assets
2,689-1,1541761,639-563
Operating Cash Flow
17,68316,96812,1168,491465
Operating Cash Flow Growth
4.21%40.05%42.69%1726.02%-84.44%

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-3,883-4,011-3,394-1,463-2,328
Sale of Property, Plant & Equipment
1495020305538
Cash Acquisitions
-77----1,031
Sale (Purchase) of Intangibles
-28-904-193-593-99
Investment in Securities
-17,009-11,046-6,035-4,2752,039
Other Investing Activities
170870-7371,255824
Investing Cash Flow
-20,817-14,145-10,327-4,771-53

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
260-1,978-1,382
Long-Term Debt Issued
4,000----
Total Debt Issued
4,260-1,978-1,382
Short-Term Debt Repaid
--892--2,390-
Long-Term Debt Repaid
-24-34-21-20-24
Total Debt Repaid
-24-926-21-2,410-24
Net Debt Issued (Repaid)
4,236-9261,957-2,4101,358
Repurchase of Common Stock
---2,537-74-
Common Dividends Paid
-902-1,078-1,708-1,004-822
Other Financing Activities
-359-103-181-142-188
Financing Cash Flow
2,975-2,107-2,469-3,630348

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
948-2206511893
Net Cash Flow
789496-615208853

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
13,80012,9578,7227,028-1,863
Free Cash Flow Growth
6.51%48.55%24.10%--
Free Cash Flow Margin
33.84%29.24%21.79%25.95%-9.57%
Free Cash Flow Per Share
77.0572.3448.5938.50-10.21
Levered Free Cash Flow
8,2078,4094,6101,964-1,849
Unlevered Free Cash Flow
8,4368,5154,6852,056-1,767

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
359176181142170
Cash Income Tax Paid
3,9773,7262,8631,775482
Change in Working Capital
6,455-1,997-3,094627-2,314